(Q35102481)

6 August 2017

1 reference

title

Understanding the new and evolving profile of adverse drug effects in schizophrenia (English)

1 reference

6 August 2017

0 references

Donna A Wirshing

1

1 reference

6 August 2017

Joseph M Pierre

series ordinal

2

1 reference

6 August 2017

Stephen M Erhart

series ordinal

3

1 reference

6 August 2017

Jennifer A Boyd

series ordinal

4

1 reference

6 August 2017

publication date

1 March 2003

1 reference

Psychiatric Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

165-190

1 reference

Differential effect of clozapine on weight: a controlled study

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Atypical antipsychotics and weight gain--a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Weight gain from novel antipsychotic drugs: need for action

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine: weight gain and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Clozapine-induced weight gain: prevalence and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Evidence for involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Effects of the obese gene product on body weight regulation in ob/ob mice

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Serum leptin levels increase rapidly after initiation of clozapine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Association of olanzapine-induced weight gain with an increase in body fat.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Novel antipsychotics and new onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Clozapine-associated diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

New-onset diabetes mellitus associated with the initiation of quetiapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effects of novel antipsychotics on glucose and lipid levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effect of clozapine on glucose metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Treatment with atypical antipsychotics: new indications and new populations

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Hyperglycemic properties of serotonin receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effects of the serotonin1A receptor agonist buspirone on tolbutamide-induced hypoglycemia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Testosterone concentrations in women and men with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Clozapine and associated diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Serum triglyceride levels in patients treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The impact of clozapine treatment on serum lipids in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine increases weight and serum triglyceride levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Novel antipsychotics and severe hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The apparent effects of ziprasidone on plasma lipids and glucose.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Weight gain associated with psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prevalence of obesity in patients receiving depot antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Elevated serum triglycerides with clozapine resolved with risperidone in four patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Update on the pharmacotherapy of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Open-label adjunctive topiramate in the treatment of bipolar disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

1 reference

7 January 2021

H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Dysrhythmia associated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Proarrhythmic effects of antidepressants and neuroleptic drugs on isolated, spontaneously beating guinea-pig Purkinje fibers

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Effects of obesity on QT, RR, and QTc intervals

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

QTc interval (cardiac repolarization): lengthening after meals.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine overdose with serum concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Cardiac effects of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prolactin and antipsychotic medications: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prolactin levels and adverse events in patients treated with risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Risperidone and associated amenorrhea: a report of 5 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Clozapine does not elevate serum prolactin levels in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Neuroleptic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Hyperprolactinemia and male sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Depression and hostility in hyperprolactinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Bromocriptine and psychosis: a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Amantadine-associated recurrence of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine use in women with antipsychotic-induced hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Return of menstruation after switching from risperidone to olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Prolactogenic effects of risperidone in male patients--a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Antipsychotic drug therapy and sexual dysfunction in men.

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

The neurobiology of sexual function

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Effects of psychotropic drugs on human erection and ejaculation

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Sexual side effects of novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine-associated priapism

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Pregnancy of a patient treated with clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Olanzapine and pregnancy. 2 case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

Antipsychotic medications and fertility

1 reference

https://api.crossref.org/works/10.1016%2FS0193-953X%2802%2900035-7

7 January 2021

10.1016/S0193-953X(02)00035-7

Identifiers

DOI

1 reference

6 August 2017

1 reference